奥精医疗
(688613)
| 流通市值：27.58亿 | | | 总市值：27.58亿 |
| 流通股本：1.37亿 | | | 总股本：1.37亿 |
| 报告期 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 156,057,979.41 | 100,036,945.54 | 42,459,701.13 | 206,033,014.77 |
| 营业收入 | 156,057,979.41 | 100,036,945.54 | 42,459,701.13 | 206,033,014.77 |
| 二、营业总成本 | 162,013,922.68 | 107,505,776 | 46,643,863.61 | 225,153,067.35 |
| 营业成本 | 48,541,200.01 | 36,896,965.89 | 16,683,324.46 | 59,600,685.73 |
| 税金及附加 | 3,787,758.65 | 2,586,417.94 | 1,112,060.98 | 3,574,003.19 |
| 销售费用 | 37,648,031.3 | 22,703,352.26 | 8,687,709.79 | 48,001,433.24 |
| 管理费用 | 43,062,612.17 | 28,655,445.67 | 14,405,225.28 | 75,597,292.33 |
| 研发费用 | 27,453,429.72 | 15,730,815.05 | 5,146,405.26 | 38,767,871.53 |
| 财务费用 | 1,520,890.83 | 932,779.19 | 609,137.84 | -388,218.67 |
| 其中:利息费用 | 1,745,187.62 | 1,181,869.43 | - | 2,946,041.75 |
| 其中:利息收入 | -293,862.46 | -272,086.85 | - | 3,498,926.17 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 9,867,996.01 | 6,907,221.52 | 3,592,200.94 | 6,350,717.03 |
| 加:投资收益 | 39,774.48 | 15,855.8 | 8,999.1 | 11,564,831.6 |
| 资产处置收益 | 154,087.33 | 170,568.35 | 201,189.53 | 637,448.22 |
| 资产减值损失(新) | - | - | - | 201,283.84 |
| 信用减值损失(新) | 3,759,669.94 | 3,759,659.92 | 475.49 | -9,234,516.71 |
| 其他收益 | 2,853,312.23 | 2,123,912.73 | 188,882.73 | 2,239,391.14 |
| 营业利润平衡项目 | 0 | 0 | 0.01 | 0 |
| 四、营业利润 | 10,718,896.72 | 5,508,387.86 | -192,414.68 | -7,360,897.46 |
| 加:营业外收入 | 30,351.03 | 29,626.21 | - | 84,821.24 |
| 减:营业外支出 | 2,686.18 | 294.35 | 294.35 | 1,660,328.75 |
| 五、利润总额 | 10,746,561.57 | 5,537,719.72 | -192,709.03 | -8,936,404.97 |
| 减:所得税费用 | 150,793.13 | 1,365.75 | - | 8,202,626.03 |
| 六、净利润 | 10,595,768.44 | 5,536,353.97 | -192,709.03 | -17,139,031 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 10,595,768.44 | 5,536,353.97 | -192,709.03 | -17,139,031 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 13,940,614.52 | 7,975,343.63 | 1,041,517.76 | -12,662,162.69 |
| 少数股东损益 | -3,344,846.08 | -2,438,989.66 | -1,234,226.79 | -4,476,868.31 |
| 扣除非经常损益后的净利润 | 3,104,487.88 | -1,784.08 | -2,341,529.84 | -28,371,119.81 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.1 | 0.06 | 0.01 | -0.09 |
| (二)稀释每股收益 | 0.1 | 0.06 | 0.01 | -0.09 |
| 八、其他综合收益 | 770,228.41 | 1,053,697.1 | 280,869.33 | -293,775.12 |
| 归属于母公司股东的其他综合收益 | 770,228.41 | 1,053,697.1 | 280,869.33 | -293,775.12 |
| 九、综合收益总额 | 11,365,996.85 | 6,590,051.07 | 88,160.3 | -17,432,806.12 |
| 归属于母公司股东的综合收益总额 | 14,710,842.93 | 9,029,040.73 | 1,322,387.09 | -12,955,937.81 |
| 归属于少数股东的综合收益总额 | -3,344,846.08 | -2,438,989.66 | -1,234,226.79 | -4,476,868.31 |
| 公告日期 | 2025-10-30 | 2025-08-30 | 2025-04-26 | 2025-04-26 |
| 审计意见(境内) | | | | 标准无保留意见 |